Antiviral combinations for severe influenza

Jake Dunning, J Kenneth Baillie, Bin Cao, Frederick G Hayden, International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC), Jake Dunning, J Kenneth Baillie, Bin Cao, Frederick G Hayden, International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC)

Abstract

Observational data suggest that the treatment of influenza infection with neuraminidase inhibitors decreases progression to more severe illness, especially when treatment is started soon after symptom onset. However, even early treatment might fail to prevent complications in some patients, particularly those infected with novel viruses such as the 2009 pandemic influenza A H1N1, avian influenza A H5N1 virus subtype, or the avian influenza A H7N9 virus subtype. Furthermore, treatment with one antiviral drug might promote the development of antiviral resistance, especially in immunocompromised hosts and critically ill patients. An obvious strategy to optimise antiviral therapy is to combine drugs with different modes of action. Because host immune responses to infection might also contribute to illness pathogenesis, improved outcomes might be gained from the combination of antiviral therapy with drugs that modulate the immune response in an infected individual. We review available data from preclinical and clinical studies of combination antiviral therapy and of combined antiviral-immunomodulator therapy for influenza. Early-stage data draw attention to several promising antiviral combinations with therapeutic potential in severe infections, but there remains a need to substantiate clinical benefit. Combination therapies with favourable experimental data need to be tested in carefully designed aclinical trials to assess their efficacy.

Copyright © 2014 Elsevier Ltd. All rights reserved.

References

    1. WHO Influenza (seasonal). Fact sheet; March, 2014. (accessed June 23, 2014).
    1. Health Protection Agency Surveillance of influenza and other respiratory viruses in the UK: 2010–2011. May, 2011 report. (accessed June 23, 2014).
    1. Centers for Disease Control and Prevention Seasonal influenza (flu). 2013–2014 influenza season week 18 ending May 3, 2014. (accessed June 23, 2014).
    1. European Centre For Disease Prevention and Control Human infection with a novel avian influenza A(H7N9) virus, China. Third update; Jan 27, 2014. (accessed June 23, 2014).
    1. Chen H, Yuan H, Gao R. Clinical and epidemiological characteristics of a fatal case of avian influenza A H10N8 virus infection: a descriptive study. Lancet. 2014;383:714–721.
    1. WHO Human infection with avian influenza A (H5N1) virus-update. Global Alert and Response (GAR); Jan 9, 2014. (accessed June 23, 2014).
    1. Kumar D, Michaels MG, Morris MI. Outcomes from pandemic influenza A H1N1 infection in recipients of solid-organ transplants: a multicentre cohort study. Lancet Infect Dis. 2010;10:521–526.
    1. Yu H, Liao Q, Yuan Y. Effectiveness of oseltamivir on disease progression and viral RNA shedding in patients with mild pandemic 2009 influenza A H1N1: opportunistic retrospective study of medical charts in China. BMJ. 2010;341:c4779.
    1. Louie JK, Yang S, Acosta M. Treatment with neuraminidase inhibitors for critically ill patients with influenza A(H1N1)pdm09. Clin Infect Dis. 2012;55:1198–1204.
    1. Muthuri SG, Myles PR, Venkatesan S, Leonardi-Bee J, Nguyen-Van-Tam JS. Impact of neuraminidase inhibitor treatment on outcomes of public health importance during the 2009–2010 influenza A(H1N1) pandemic: a systematic review and meta-analysis in hospitalized patients. J Infect Dis. 2013;207:553–563.
    1. Hsu J, Santesso N, Mustafa R. Antivirals for treatment of influenza: a systematic review and meta-analysis of observational studies. Ann Intern Med. 2012;156:512–524.
    1. Siston AM, Rasmussen SA, Honein MA. Pandemic 2009 influenza A(H1N1) virus illness among pregnant women in the United States. JAMA. 2010;303:1517–1525.
    1. Dubar G, Azria E, Tesniere A. French experience of 2009 A/H1N1v influenza in pregnant women. PLoS One. 2010;5:e13112.
    1. Muthuri SG, Venkatesan S, Myles PR. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. Lancet Respir Med. 2014;2:395–404.
    1. Chan PK, Lee N, Zaman M. Determinants of antiviral effectiveness in influenza virus A subtype H5N1. J Infect Dis. 2012;206:1359–1366.
    1. Nukiwa N, Kamigaki T, Oshitani H. Fatal cases of pandemic (H1N1) 2009 influenza despite their early antiviral treatment in Japan. Clin Infect Dis. 2010;51:993–994.
    1. Hu Y, Lu S, Song Z. Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance. Lancet. 2013;381:2273–2279.
    1. To KK, Hung IF, Li IW. Delayed clearance of viral load and marked cytokine activation in severe cases of pandemic H1N1 2009 influenza virus infection. Clin Infect Dis. 2010;50:850–859.
    1. Lee N, Ison MG. Diagnosis, management and outcomes of adults hospitalized with influenza. Antivir Ther. 2012;17:143–157.
    1. Malato L, Llavador V, Marmier E. Pandemic influenza A(H1N1) 2009: molecular characterisation and duration of viral shedding in intensive care patients in Bordeaux, south-west France, May 2009 to January 2010. Euro Surveill. 2011;16:19776.
    1. Hurt AC, Chotpitayasunondh T, Cox NJ. Antiviral resistance during the 2009 influenza A H1N1 pandemic: public health, laboratory, and clinical perspectives. Lancet Infect Dis. 2011;12:240–248.
    1. de Jong MD, Tran TT, Truong HK. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med. 2005;353:2667–2672.
    1. Gao HN, Lu HZ, Cao B. Clinical findings in 111 cases of influenza A (H7N9) virus infection. N Engl J Med. 2013;368:2277–2285.
    1. Perelson AS, Rong L, Hayden FG. Combination antiviral therapy for influenza: predictions from modeling of human infections. J Infect Dis. 2012;205:1642–1645.
    1. Hsieh YH, Tsai CA, Lin CY. Asymptomatic ratio for seasonal H1N1 influenza infection among schoolchildren in Taiwan. BMC Infect Dis. 2014;14:80.
    1. Ludwig S. Disruption of virus-host cell interactions and cell signaling pathways as an anti-viral approach against influenza virus infections. Biol Chem. 2011;392:837–847.
    1. Hayden FG. Combinations of antiviral agents for treatment of influenza virus infections. J Antimicrob Chemother. 1986;18(suppl B):177–183.
    1. Hayden FG. Newer influenza antivirals, biotherapeutics and combinations. Influenza Other Respir Viruses. 2013;7(suppl 1):63–75.
    1. Lavrov SV, Eremkina EI, Orlova TG, Galegov GA, Soloviev VD, Zhdanov VM. Combined inhibition of influenza virus reproduction in cell culture using interferon and amantadine. Nature. 1968;217:856–857.
    1. Galegov GA, Pushkarskaya NL, Obrosova-Serova NP, Zhdanov VM. Combined action of ribovirin and rimantadine in experimental myxovirus infection. Experientia. 1977;33:905–906.
    1. Wilson SZ, Knight V, Wyde PR, Drake S, Couch RB. Amantadine and ribavirin aerosol treatment of influenza A and B infection in mice. Antimicrob Agents Chemother. 1980;17:642–648.
    1. Pushkarskaia NL, L'vov ND, Galegov GA. Prevention of the formation of a mutant influenza A virus resistant to rimantadine (alpha-methyl-1-adamantanemethylamine hydrochloride) by using ribavirin (1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide) Vopr Virusol. 1980;3:303–306.
    1. Ilyushina NA, Bovin NV, Webster RG, Govorkova EA. Combination chemotherapy, a potential strategy for reducing the emergence of drug-resistant influenza A variants. Antiviral Res. 2006;70:121–131.
    1. Hayden FG, Schlepushkin AN, Pushkarskaya NL. Combined interferon-alpha 2, rimantadine hydrochloride, and ribavirin inhibition of influenza virus replication in vitro. Antimicrob Agents Chemother. 1984;25:53–57.
    1. Ilyushina NA, Hoffmann E, Salomon R, Webster RG, Govorkova EA. Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice. Antivir Ther. 2007;12:363–370.
    1. Leneva IA, Roberts N, Govorkova EA, Goloubeva OG, Webster RG. The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses. Antiviral Res. 2000;48:101–115.
    1. Govorkova EA, Fang HB, Tan M, Webster RG. Neuraminidase inhibitor-rimantadine combinations exert additive and synergistic anti-influenza virus effects in MDCK cells. Antimicrob Agents Chemother. 2004;48:4855–4863.
    1. Galabov AS, Simeonova L, Gegova G. Rimantadine and oseltamivir demonstrate synergistic combination effect in an experimental infection with type A (H3N2) influenza virus in mice. Antivir Chem Chemother. 2006;17:251–258.
    1. Bantia S, Kellogg D, Parker CD, Babu YS. Combination of peramivir and rimantadine demonstrate synergistic antiviral effects in sub-lethal influenza A (H3N2) virus mouse model. Antiviral Res. 2010;88:276–280.
    1. Madren LK, Shipman C, Jr, Hayden FG. In vitro inhibitory effects of combinations of anti-influenza agents. Antivir Chem & Chemother. 1995;2:109–113.
    1. Ison MG, Gnann JW, Jr., Nagy-Agren S. Safety and efficacy of nebulized zanamivir in hospitalized patients with serious influenza. Antivir Ther. 2003;8:183–190.
    1. Duval X, van der WS, Blanchon T. Efficacy of oseltamivir-zanamivir combination compared to each monotherapy for seasonal influenza: a randomized placebo-controlled trial. PLoS Med. 2010;7:e1000362.
    1. Atiee G, Lasseter K, Baughman S. Absence of pharmacokinetic interaction between intravenous peramivir and oral oseltamivir or rimantadine in humans. J Clin Pharmacol. 2012;52:1410–1419.
    1. Pukrittayakamee S, Jittamala P, Stepniewska K. An open-label crossover study to evaluate potential pharmacokinetic interactions between oral oseltamivir and intravenous zanamivir in healthy Thai adults. Antimicrob Agents Chemother. 2011;55:4050–4057.
    1. Hung IF, To KK, Lee CK. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis. 2011;52:447–456.
    1. Wang CH, Chung FT, Lin SM. Adjuvant treatment with a mammalian target of rapamycin inhibitor, sirolimus, and steroids improves outcomes in patients with severe H1N1 pneumonia and acute respiratory failure. Crit Care Med. 2014;42:313–321. 122.
    1. Boivin G. Detection and management of antiviral resistance for influenza viruses. Influenza Other Respir Viruses. 2013;7(suppl 3):18–23.
    1. Nguyen JT, Hoopes JD, Le MH. Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro. PLoS One. 2010;5:e9332.
    1. Smee DF, Hurst BL, Wong MH. Combinations of oseltamivir and peramivir for the treatment of influenza A (H1N1) virus infections in cell culture and in mice. Antiviral Res. 2010;88:38–44.
    1. Russell RJ, Haire LF, Stevens DJ. The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. Nature. 2006;443:45–49.
    1. Collins PJ, Haire LF, Lin YP. Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants. Nature. 2008;453:1258–1261.
    1. Smith BJ, McKimm-Breshkin JL, McDonald M, Fernley RT, Varghese JN, Colman PM. Structural studies of the resistance of influenza virus neuramindase to inhibitors. J Med Chem. 2002;45:2207–2212.
    1. Molla A, Kati W, Carrick R. In vitro selection and characterization of influenza A (A/N9) virus variants resistant to a novel neuraminidase inhibitor, A-315675. J Virol. 2002;76:5380–5386.
    1. Yen HL, McKimm-Breschkin JL, Choy KT. Resistance to neuraminidase inhibitors conferred by an R292K mutation in a human influenza virus H7N9 isolate can be masked by a mixed R/K viral population. MBio. 2013;4:e00396–e00413.
    1. Watanabe T, Kiso M, Fukuyama S. Characterization of H7N9 influenza A viruses isolated from humans. Nature. 2013;501:551–555.
    1. Cao B, Hayden FG. Therapy of H7N9 pneumonia: current perspectives. Expert Rev Anti Infect Ther. 2013;11:1123–1126.
    1. Hai R, Schmolke M, Leyva-Grado VH. Influenza A(H7N9) virus gains neuraminidase inhibitor resistance without loss of in vivo virulence or transmissibility. Nat Commun. 2013;4:2854.
    1. Carrat F, Duval X, Tubach F. Effect of oseltamivir, zanamivir or oseltamivir-zanamivir combination treatments on transmission of influenza in households. Antivir Ther. 2012;17:1085–1090.
    1. Escuret V, Cornu C, Boutitie F. Oseltamivir-zanamivir bitherapy compared to oseltamivir monotherapy in the treatment of pandemic 2009 influenza A(H1N1) virus infections. Antiviral Res. 2012;96:130–137.
    1. Fraaij PL, van der Vries E, Beersma MF. Evaluation of the antiviral response to zanamivir administered intravenously for treatment of critically ill patients with pandemic influenza A (H1N1) infection. J Infect Dis. 2011;204:777–782.
    1. Petersen E, Keld DB, Ellermann-Eriksen S. Failure of combination oral oseltamivir and inhaled zanamivir antiviral treatment in ventilator- and ECMO-treated critically ill patients with pandemic influenza A (H1N1)v. Scand J Infect Dis. 2011;43:495–503.
    1. Govorkova EA, Baranovich T, Seiler P. Antiviral resistance among highly pathogenic influenza A (H5N1) viruses isolated worldwide in 2002–2012 shows need for continued monitoring. Antiviral Res. 2013;98:297–304.
    1. Hayden FG, Douglas RG, Jr, Simons R. Enhancement of activity against influenza viruses by combinations of antiviral agents. Antimicrob Agents Chemother. 1980;18:536–541.
    1. Burlington DB, Meiklejohn G, Mostow SR. Anti-influenza A activity of combinations of amantadine and ribavirin in ferret tracheal ciliated epithelium. J Antimicrob Chemother. 1983;11:7–14.
    1. Smee DF, Hurst BL, Wong MH, Bailey KW, Morrey JD. Effects of double combinations of amantadine, oseltamivir, and ribavirin on influenza A (H5N1) virus infections in cell culture and in mice. Antimicrob Agents Chemother. 2009;53:2120–2128.
    1. Nguyen JT, Smee DF, Barnard DL. Efficacy of combined therapy with amantadine, oseltamivir, and ribavirin in vivo against susceptible and amantadine-resistant influenza A viruses. PLoS One. 2012;7:e31006.
    1. Morrison D, Roy S, Rayner C. A randomized, crossover study to evaluate the pharmacokinetics of amantadine and oseltamivir administered alone and in combination. PLoS One. 2007;2:e1305.
    1. Smee DF, Bailey KW, Morrison AC, Sidwell RW. Combination treatment of influenza A virus infections in cell culture and in mice with the cyclopentane neuraminidase inhibitor RWJ-270201 and ribavirin. Chemotherapy. 2002;48:88–93.
    1. Smee DF, Wong MH, Bailey KW, Sidwell RW. Activities of oseltamivir and ribavirin used alone and in combination against infections in mice with recent isolates of influenza A (H1N1) and B viruses. Antivir Chem Chemother. 2006;17:185–192.
    1. Ilyushina NA, Hay A, Yilmaz N, Boon AC, Webster RG, Govorkova EA. Oseltamivir-ribavirin combination therapy for highly pathogenic H5N1 influenza virus infection in mice. Antimicrob Agents Chemother. 2008;52:3889–3897.
    1. Smee DF, Wong MH, Bailey KW, Sidwell RW. Activities of oseltamivir and ribavirin used alone and in combination against infections in mice with recent isolates of influenza A (H1N1) and B viruses. Antivir Chem Chemother. 2006;17:185–192.
    1. Smith CB, Charette RP, Fox JP, Cooney MK, Hall CE. Lack of effect of oral ribavirin in naturally occurring influenza A virus (H1N1) infection. J Infect Dis. 1980;141:548–554.
    1. Stein DS, Creticos CM, Jackson GG. Oral ribavirin treatment of influenza A and B. Antimicrob Agents Chemother. 1987 Aug;31:1285–1287.
    1. Ray CG, Icenogle TB, Minnich LL, Copeland JG, Grogan TM. The use of intravenous ribavirin to treat influenza virus-associated acute myocarditis. J Infect Dis. 1989;159:829–836.
    1. Hayden FG, Sable CA, Connor JD, Lane J. Intravenous ribavirin by constant infusion for serious influenza and parainfluenzavirus infection. Antivir Ther. 1996;1:51–56.
    1. Kirshon B, Faro S, Zurawin RK, Samo TC, Carpenter RJ. Favorable outcome after treatment with amantadine and ribavirin in a pregnancy complicated by influenza pneumonia. A case report. J Reprod Med. 1988;33:399–401.
    1. Chan-Tack KM, Murray JS, Birnkrant DB. Use of ribavirin to treat influenza. N Engl J Med. 2009;361:1713–1714.
    1. Nguyen JT, Hoopes JD, Smee DF. Triple combination of oseltamivir, amantadine, and ribavirin displays synergistic activity against multiple influenza virus strains in vitro. Antimicrob Agents Chemother. 2009;53:4115–4126.
    1. Hoopes JD, Driebe EM, Kelley E. Triple combination antiviral drug (TCAD) composed of amantadine, oseltamivir, and ribavirin impedes the selection of drug-resistant influenza A virus. PLoS One. 2011;6:e29778.
    1. Seo S, Englund JA, Nguyen JT. Combination therapy with amantadine, oseltamivir and ribavirin for influenza A infection: safety and pharmacokinetics. Antivir Ther. 2012;18:377–386.
    1. Kim WY, Young SG, Huh JW. Triple-combination antiviral drug for pandemic H1N1 influenza virus infection in critically ill patients on mechanical ventilation. Antimicrob Agents Chemother. 2011;55:5703–5709.
    1. Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smee DF, Barnard DL. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res. 2013;100:446–454.
    1. Smee DF, Hurst BL, Wong MH. Effects of the combination of favipiravir (T-705) and oseltamivir on influenza A virus infections in mice. Antimicrob Agents Chemother. 2010;54:126–133.
    1. Tarbet EB, Maekawa M, Furuta Y, Babu YS, Morrey JD, Smee DF. Combinations of favipiravir and peramivir for the treatment of pandemic influenza A/California/04/2009 (H1N1) virus infections in mice. Antiviral Res. 2012;94:103–110.
    1. Toyama Chemical Co. The new drug application approval of “AVIGAN® tablet 200mg” in Japan for the anti-influenza virus drug. March 24, 2014. (accessed June 23, 2014).
    1. Kobayashi O, Kashiwagi S, Iwamoto A. Clinical effectiveness and safety of favipiravir, a novel anti-influenza drug with a selective inhibition activity against viral RNA polymerase. 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Chicago, IL, USA; Sept 9–17, 2011. V-405.
    1. Epstein C. A phase 2, randomized, double blind, placebo-controlled, multicenter study evaluating the safety and pharmacokinetics of different dosing regimens of favipiravir (T-705) in adult subjects with uncomplicated influenza. Abstact O-905. Options for Control of Influenza VII; Cape Town, South Africa; Sept 5–10, 2013.
    1. Zhou B, Zhong N, Guan Y. Treatment with convalescent plasma for influenza A (H5N1) infection. N Engl J Med. 2007;357:1450–1451.
    1. Hung IF, To KK, Lee CK. Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection. Chest. 2013;144:464–473.
    1. Ekiert DC, Wilson IA. Broadly neutralizing antibodies against influenza virus and prospects for universal therapies. Curr Opin Virol. 2012;2:134–141.
    1. Ekiert DC, Friesen RH, Bhabha G. A highly conserved neutralizing epitope on group 2 influenza A viruses. Science. 2011;333:843–850.
    1. Corti D, Voss J, Gamblin SJ. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science. 2011;333:850–856.
    1. Nakamura G, Chai N, Park S. An in vivo human-plasmablast enrichment technique allows rapid identification of therapeutic influenza a antibodies. Cell Host Microbe. 2013;14:93–103.
    1. Wathen MW, Barro M, Bright RA. Antivirals in seasonal and pandemic influenza–future perspectives. Influenza Other Respir Viruses. 2013;7(suppl 1):76–80.
    1. Ashton LV, Callan RL, Rao S, Landolt GA. In vitro susceptibility of canine influenza A (H3N8) virus to nitazoxanide and tizoxanide. Vet Med Int. 2010;2010:1–5.
    1. Belardo G, La Frazia S, Cenciareli O, Carta S, Rossignol JF, Santoro MG. A novel potential anti-influenza drug, acting in synergism with neuraminidase inhibitors [Internet]. Paper presented at: 49th Infectious Disease Society of America Annual Meeting: New Approaches to Anti-Viral Therapy; Boston, MA; Oct 20–23, 2011. (accessed April 29, 2014).
    1. Rossignol JF, La Frazia S, Chiappa L, Ciucci A, Santoro MG. Thiazolides, a new class of anti-influenza molecules targeting viral hemagglutinin at the post-translational level. J Biol Chem. 2009;284:29798–29808.
    1. Rossignol JF, Samudrals S, Hoppers M, Haffizulla J. A randomized, double-blind, placebo (PCB) controlled clinical trial of nitazoxanide (NTZ) in adults and adolescents with acute uncomplicated influenza [Internet]. Paper presented at the 49th Infectious Disease Society of America Annual Meeting; Boston, MA; Oct 20–23, 2011 (cited Apr 29, 2013); DSA Annual Meeting, Boston. LB-35. Oct 22, 2011. (accessed June 23, 2014).
    1. Malakhov MP, Aschenbrenner LM, Smee DF. Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection. Antimicrob Agents Chemother. 2006;50:1470–1479.
    1. Belser JA, Lu X, Szretter KJ. DAS181, a novel sialidase fusion protein, protects mice from lethal avian influenza H5N1 virus infection. J Infect Dis. 2007;196:1493–1499.
    1. Triana-Baltzer GB, Gubareva LV, Nicholls JM. Novel pandemic influenza A(H1N1) viruses are potently inhibited by DAS181, a sialidase fusion protein. PLoS One. 2009;4:e7788.
    1. Triana-Baltzer GB, Sanders RL, Hedlund M. Phenotypic and genotypic characterization of influenza virus mutants selected with the sialidase fusion protein DAS181. J Antimicrob Chemother. 2011;66:15–28.
    1. Moss RB, Hansen C, Sanders RL, Hawley S, Li T, Steigbigel RT. A phase II study of DAS181, a novel host directed antiviral for the treatment of influenza infection. J Infect Dis. 2012;206:1844–1851.
    1. Chen YB, Driscoll JP, McAfee SL. Treatment of parainfluenza 3 infection with DAS181 in a patient after allogeneic stem cell transplantation. Clin Infect Dis. 2011;53:e77–e80.
    1. Drozd DR, Limaye AP, Moss RB. DAS181 treatment of severe parainfluenza type 3 pneumonia in a lung transplant recipient. Transpl Infect Dis. 2013;15:E28–E32.
    1. Boriskin YS, Leneva IA, Pecheur EI, Polyak SJ. Arbidol: a broad-spectrum antiviral compound that blocks viral fusion. Curr Med Chem. 2008;15:997–1005.
    1. Leneva IA, Russell RJ, Boriskin YS, Hay AJ. Characteristics of arbidol-resistant mutants of influenza virus: implications for the mechanism of anti-influenza action of arbidol. Antiviral Res. 2009;81:132–140.
    1. Shi L, Xiong H, He J. Antiviral activity of arbidol against influenza A virus, respiratory syncytial virus, rhinovirus, coxsackie virus and adenovirus in vitro and in vivo. Arch Virol. 2007;152:1447–1455.
    1. Leneva IA, Fediakina IT, Gus'kova TA, Glushkov RG. Sensitivity of various influenza virus strains to arbidol. Influence of arbidol combination with different antiviral drugs on reproduction of influenza virus A. Ter Arkh. 2005;77:84–88. (in Russian).
    1. Vertex Press Release VX-787 showed significant antiviral activity and reduced the severity and duration of influenza symptoms in phase 2 challenge study. (accessed June 23, 2014).
    1. Iversen PL, Mourich DV, Voss T. AVI-7100 is effective in oseltamivir resistant H1N1 infected ferrets. Abstract F1-13725a. Presented at the 51st Interscience conference on Antimicrobial Agents and Chemoterapy (ICAAC). Chicago, IL, USA; Sept 17–20, 2011.
    1. Iverson PL, Mourich DV, Voss T, Bothwell WA. AVI-7100 prevents transmission from oseltamivir resistant H1N1 viral infected to naïve ferrets. Presented at the 51st Interscience conference on Antimicrobial Agents and Chemotherapy (ICAAC). Chicago, IL, USA; Sept 17–20, 2011.
    1. Hui DS, Lee N, Chan PK. Adjunctive therapies and immunomodulatory agents in the management of severe influenza. Antiviral Res. 2013;98:410–416.
    1. Fedson DS. Treating influenza with statins and other immunomodulatory agents. Antiviral Res. 2013;99:417–435.
    1. Sanderson SD, Thoman ML, Kis K. Innate immune induction and influenza protection elicited by a response-selective agonist of human C5a. PLoS One. 2012;7:e40303.
    1. Goulet ML, Olagnier D, Xu Z. Systems analysis of a RIG-I agonist inducing broad spectrum inhibition of virus infectivity. PLoS Pathog. 2013;9:e1003298.
    1. Shirey KA, Lai W, Scott AJ. The TLR4 antagonist Eritoran protects mice from lethal influenza infection. Nature. 2013;497:498–502.
    1. Morita M, Kuba K, Ichikawa A. The lipid mediator protectin D1 inhibits influenza virus replication and improves severe influenza. Cell. 2013;153:112–125.
    1. Lejal N, Tarus B, Bouguyon E. Structure-based discovery of the novel antiviral properties of naproxen against the nucleoprotein of influenza A virus. Antimicrob Agents Chemother. 2013;57:2231–2242.
    1. Ison MG, de Jong MD, Gilligan KJ. End points for testing influenza antiviral treatments for patients at high risk of severe and life-threatening disease. J Infect Dis. 2010;201:1654–1662.
    1. Murray JL, McDonald NJ, Sheng J. Inhibition of influenza A virus replication by antagonism of a PI3K-AKT-mTOR pathway member identified by gene-trap insertional mutagenesis. Antivir Chem Chemother. 2012;22:205–215.
    1. Haasbach E, Hartmayer C, Planz O. Combination of MEK inhibitors and oseltamivir leads to synergistic antiviral effects after influenza A virus infection in vitro. Antiviral Res. 2013;98:319–324.
    1. Ghezzi P, Ungheri D. Synergistic combination of N-acetylcysteine and ribavirin to protect from lethal influenza viral infection in a mouse model. Int J Immunopathol Pharmacol. 2004;17:99–102.
    1. Garozzo A, Tempera G, Ungheri D, Timpanaro R, Castro A. N-acetylcysteine synergizes with oseltamivir in protecting mice from lethal influenza infection. Int J Immunopathol Pharmacol. 2007;20:349–354.
    1. Walsh KB, Teijaro JR, Wilker PR. Suppression of cytokine storm with a sphingosine analog provides protection against pathogenic influenza virus. Proc Natl Acad Sci USA. 2011;108:12018–12023.
    1. Zheng BJ, Chan KW, Lin YP. Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza A/H5N1 virus. Proc Natl Acad Sci USA. 2008;105:8091–8096.
    1. D'Agostini C, Palamara AT, Favalli C. Efficacy of combination therapy with amantadine, thymosin alpha 1 and alpha/beta interferon in mice infected with influenza A virus. Int J Immunopharmacol. 1996;18:95–102.
    1. Fukushi M, Yamashita M, Miyoshi-Akiyama T, Kubo S, Yamamoto K, Kudo K. Laninamivir octanoate and artificial surfactant combination therapy significantly increases survival of mice infected with lethal influenza H1N1 virus. PLoS One. 2012;7:e42419.
    1. Perwitasari O, Yan X, Johnson S. Targeting organic anion transporter 3 with probenecid as a novel anti-influenza a virus strategy. Antimicrob Agents Chemother. 2013;57:475–483.
    1. Wattanagoon Y, Stepniewska K, Lindegardh N. Pharmacokinetics of high-dose oseltamivir in healthy volunteers. Antimicrob Agents Chemother. 2009;53:945–952.
    1. Belser JA, Szretter KJ, Katz JM, Tumpey TM. Simvastatin and oseltamivir combination therapy does not improve the effectiveness of oseltamivir alone following highly pathogenic avian H5N1 influenza virus infection in mice. Virology. 2013;439:42–46.
    1. An SC, Xu LL, Li FD, Bao LL, Qin C, Gao ZC. Triple combinations of neuraminidase inhibitors, statins and fibrates benefit the survival of patients with lethal avian influenza pandemic. Med Hypotheses. 2011;77:1054–1057.
    1. Viasus D, Pano-Pardo JR, Cordero E. Effect of immunomodulatory therapies in patients with pandemic influenza A (H1N1) 2009 complicated by pneumonia. J Infect. 2011;62:193–199.
    1. Ishii H, Komiya K, Yamagata E. Clarithromycin has limited effects in non-elderly, non-severe patients with seasonal influenza virus A infection. J Infect. 2012;64:343–345.
    1. Martin-Loeches I, Bermejo-Martin JF, Valles J. Macrolide-based regimens in absence of bacterial co-infection in critically ill H1N1 patients with primary viral pneumonia. Intensive Care Med. 2013;39:693–702.
    1. Vandermeer ML, Thomas AR, Kamimoto L. Association between use of statins and mortality among patients hospitalized with laboratory-confirmed influenza virus infections: a multistate study. J Infect Dis. 2012;205:13–19.
    1. Mortensen EM, Nakashima B, Cornell J. Population-based study of statins, angiotensin II receptor blockers, and angiotensin-converting enzyme inhibitors on pneumonia-related outcomes. Clin Infect Dis. 2012;55:1466–1473.
    1. Chopra V, Rogers MA, Buist M. Is statin use associated with reduced mortality after pneumonia? A systematic review and meta-analysis. Am J Med. 2012;125:1111–1123.
    1. Makris D, Manoulakas E, Komnos A. Effect of pravastatin on the frequency of ventilator-associated pneumonia and on intensive care unit mortality: open-label, randomized study. Crit Care Med. 2011;39:2440–2446.
    1. Baron S, Isaacs A. Absence of interferon in lungs fom fatal cases of influenza. BMJ. 1962;1:18–20.
    1. Agrati C, Gioia C, Lalle E. Association of profoundly impaired immune competence in H1N1v-infected patients with a severe or fatal clinical course. J Infect Dis. 2010;202:681–689.
    1. Szretter KJ, Gangappa S, Belser JA. Early control of H5N1 influenza virus replication by the type I interferon response in mice. J Virol. 2009;83:5825–5834.
    1. Matzinger SR, Carroll TD, Fritts L, McChesney MB, Miller CJ. Exogenous IFN-alpha administration reduces influenza A virus replication in the lower respiratory tract of rhesus macaques. PLoS One. 2011;6:e29255.
    1. Loutfy MR, Blatt LM, Siminovitch KA. Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study. JAMA. 2003;290:3222–3228.
    1. Lee SM, Cheung CY, Nicholls JM. Hyperinduction of cyclooxygenase-2-mediated proinflammatory cascade: a mechanism for the pathogenesis of avian influenza H5N1 infection. J Infect Dis. 2008;198:525–535.
    1. Brun-Buisson C, Richard JC, Mercat A, Thiebaut AC, Brochard L. Early corticosteroids in severe influenza A/H1N1 pneumonia and acute respiratory distress syndrome. Am J Respir Crit Care Med. 2011;183:1200–1206.
    1. Martin-Loeches I, Lisboa T, Rhodes A. Use of early corticosteroid therapy on ICU admission in patients affected by severe pandemic (H1N1)v influenza A infection. Intensive Care Med. 2011;37:272–283.
    1. Xi X, Xu Y, Jiang L, Li A, Duan J, Du B. Hospitalized adult patients with 2009 influenza A(H1N1) in Beijing, China: risk factors for hospital mortality. BMC Infect Dis. 2010;10:256.
    1. Kim SH, Hong SB, Yun SC. Corticosteroid treatment in critically ill patients with pandemic influenza A/H1N1 2009 infection: analytic strategy using propensity scores. Am J Respir Crit Care Med. 2011;183:1207–1214.
    1. Chan K. Chinese medicinal materials and their interface with western medical concepts. J Ethnopharmacol. 2005;96:1–18.
    1. Wang C, Cao B, Liu QQ. Oseltamivir compared with the Chinese traditional therapy maxingshigan-yinqiaosan in the treatment of H1N1 influenza: a randomized trial. Ann Intern Med. 2011;155:217–225.
    1. Hayden FG. Experimental human influenza: observations from studies of influenza antivirals. Antivir Ther. 2012;17:133–141.
    1. Kairalla JA, Coffey CS, Thomann MA, Muller KE. Adaptive trial designs: a review of barriers and opportunities. Trials. 2012;13:145.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren